Flynn James E 13D and 13G filings for Larimar Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-03-15 4:37 pm Purchase |
2024-03-14 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 21,273,474 33.320% |
8,300 (+0.04%) |
Filing |
| 2024-02-16 2:11 pm Purchase |
2024-02-16 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 21,265,174 34.820% |
4,291,539 (+25.28%) |
Filing |
| 2024-02-15 5:20 pm Unchanged |
2024-02-13 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 16,973,635 39.200% |
0 (Unchanged) |
Filing |
| 2023-03-16 5:41 pm Purchase |
2023-03-14 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 16,973,635 39.200% |
10,606 (+0.06%) |
Filing |
| 2022-09-16 5:19 pm Purchase |
2022-09-16 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 16,963,029 42.450% |
11,126,786 (+190.65%) |
Filing |
| 2021-07-02 5:08 pm Purchase |
2021-06-30 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 5,836,243 32.940% |
686,171 (+13.32%) |
Filing |
| 2021-05-26 1:48 pm Unchanged |
2021-05-25 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 5,150,072 33.500% |
0 (Unchanged) |
Filing |
| 2021-05-21 5:05 pm Purchase |
2021-05-21 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 5,150,072 33.500% |
5,533 (+0.11%) |
Filing |
| 2020-07-01 4:01 pm Sale |
2020-06-26 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 5,144,539 33.500% |
-946,711 (-15.54%) |
Filing |
| 2020-06-08 5:10 pm Purchase |
2020-05-28 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 6,091,250 39.760% |
6,091,250 (New Position) |
Filing |